RxDoctor Payments Data

Bambi Gladfelter, DO

Family Medicine · Richmond, VANPI 1588854277

Payments from drug & device makers

$6,790in general payments, 2019–2025

Across 435 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$472
  • AbbVie$416
  • Amgen$407
  • Pfizer$248
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,73199%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,790 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$60,889
Medicare patients
111
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$25,458
FarxigaDapagliflozin Propanediol18$11,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,782
MyrbetriqMirabegron12$6,420
Repatha SureclickEvolocumab12$6,407
Clonidine19$4,628
Estradiol17$1,644
Rosuvastatin Calcium126$1,525
Nebivolol Hcl20$923
Losartan Potassium91$842
Levothyroxine Sodium101$842
Omeprazole55$775
Albuterol Sulfate HfaAlbuterol Sulfate22$691
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$623
Gabapentin44$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,458$25,45820 claims
AstraZenecaFarxiga$1,000$11,28618 claims
GSKTrelegy Ellipta$241$10,78216 claims
Astellas Pharma US IncMyrbetriq$50$6,42012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$45$842101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →